Analysts' Perspective: Sarepta (SRPT), FleetCor (FLT), Lumentum (LITE), Depomed (DEPO), Glencore (GLNCY)
Brokerage firm RBC Capital Markets upgraded Sarepta Therapeutics Inc. (Nasdaq:SRPT) shares from a Sector Perform to an Outperform rating and boosted its price target from $5.00 to $83.00, while analysts at Jefferies upgraded the company's stock from Underperform to Hold.
Separately, investment analysts at Robert W. Baird increased their price objective on shares of the biopharmaceutical company from $23.00 to $102.00, while maintaining an Outperform rating
Sarepta Therapeutics said on Monday that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its drug EXONDYS 51™ (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per kilogram for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.
Duchenne Muscular Dystrophy is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death.
Sarepta Therapeuticsis focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.
Equities researchers at Monness Crespi & Hardt reiterated a Buy rating and raised their price target on FleetCor Technologies, Inc. (NYSE:FLT) stock from $173.00 to $186.00
FleetCor Technologies is an independent global provider of fuel cards, commercial payment and data solutions, stored value solutions, and workforce payment products and services to businesses, retailers, commercial fleets, oil companies, petroleum marketers and government entities in countries throughout North America, Latin America, Europe, Australia and New Zealand.
Analysts at Needham increased their price target on shares of Lumentum Holdings Inc. (Nasdaq:LITE) from $40.00 to $50.00 while maintaining a Strong Buy rating
Lumentum Holdings is a provider of optical and photonic products for a range of end market applications, including data communications (Datacom) and telecommunications (Telecom) networking and commercial lasers (commercial lasers) for manufacturing, inspection and life-science applications.
Mizuho reiterated its Buy rating on Depomed Inc. (Nasdaq:DEPO) stock while increasing its price target from $23.00 to $27.00
Depomed is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions
Shares of Glencore PLC (OTCMKTS:GLNCY) were upgraded at Credit Suisse from a Neutral to an Outperform rating
Glencore is an integrated producer and marketer of natural resources, with activities in the production, refinement, processing, storage, transport and marketing of metals and minerals, energy products and agricultural products.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer